Mosunetuzumab for clearing CLL cells after other treatments
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a drug called mosunetuzumab to see if it can clear remaining cancer cells (minimal residual disease) in people with CLL or SLL who have already had certain treatments. It may help those whose blood tests show very low levels of leftover disease after BTK inhibitor or BCL2 inhibitor therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have CLL or SLL and have completed or are still on a BTK inhibitor (like ibrutinib) for over 12 months, including at least 2 months at the same dose, or finished a BCL2-based treatment (like venetoclax plus obinutuzumab) less than 12 months ago.
- Your BTK or BCL2 treatment was the first or second line of therapy for your CLL.
- You have a small amount of leftover disease in your blood or bone marrow, detected by a sensitive test (called MRD positive, ≥ 10e-4).
- You are at least 18 years old, can take oral medicines, and are generally well enough for daily activities (ECOG score 0 to 2).
- You do not have large lymph nodes over 5 cm, very high white blood cell counts, or signs that CLL is getting worse.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different combinations of targeted drugs for people with CLL or SLL who have not had prior treatment for their disease. The goal is to see if these combinations are safe and effective.
This trial tests a combination of two drugs (mosunetuzumab and zanubrutinib) for people with marginal zone lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help control the lymphoma.
This trial studies mosunetuzumab alone or combined with zanubrutinib to treat people with follicular lymphoma that is advanced or causing problems. It’s meant to see which approach works better and is safe for long-term treatment.
This trial tests whether adding a new drug, sonrotoclax, to the standard treatment zanubrutinib works better for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. It's for patients aged 65 and older who need therapy due to symptoms or blood cell issues.
This Phase 2 study tests whether mosunetuzumab, added to lenalidomide, can treat people who have not yet received lymphoma medicines. It’s for follicular lymphoma or marginal zone lymphoma and may help shrink tumors and improve control of the disease.
This study tests a new antibody drug called mosunetuzumab in patients with chronic lymphocytic leukemia (CLL) who have already tried other treatments and still have detectable leukemia cells in their bone marrow. The drug is designed to work in a way that might help your immune system fight the remaining cancer cells.
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.